MedTrace Logo

Acute Effects of Chemotherapy Administration on Skeletal Muscle of Breast Cancer Patients: the PROTECT-06 Study

NCT05128617 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-06-08

No results posted yet for this study

Summary

Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe off-target side effects such as skeletal muscle deconditioning. To date, three different studies investigated skeletal muscle decontioning in breast cancer patients, through long term protocols including all chemotherapy cycle treatment, and highlighted both structural alterations and impaired cellular processes. However, no study is currently availbale on the acute effect of one single chemotherapy administration in breast cancer patients skeletal muscle tissue. Our study is therefore dedicated to the investigation of the acute effect of the first dose administration of both Epuribicin/cyclophosphamide and Paclitaxel chemotherapies on skeletal muscle of breast cancer patients.

Conditions

Interventions

DRUG

Epirubicin-cyclophosphamide

1 cycle of Epirubicin-cyclophosphamide

DRUG

Paclitaxel

1 cycle of Paclitaxel

Sponsors & Collaborators

  • Université de Strasbourg - Unité de Recherche 3072 - Mitochondries, Stress oxydant, Protection musculaire

    collaborator UNKNOWN

  • Institut de cancérologie Strasbourg Europe

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-04
Primary Completion
2023-05-30
Completion
2023-05-30

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05128617 on ClinicalTrials.gov